influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma

Background Prediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We investigated whether HBV DNA level and antiviral therapy are associated with HCC recurrence. Methods This retrospective study involved 103 patients who...

Full description

Saved in:
Bibliographic Details
Published inJournal of gastroenterology Vol. 44; no. 9; pp. 991 - 999
Main Authors Chuma, Makoto, Hige, Shuhei, Kamiyama, Toshiya, Meguro, Takashi, Nagasaka, Atsushi, Nakanishi, Kazuaki, Yamamoto, Yoshiya, Nakanishi, Mitsuru, Kohara, Toshihisa, Sho, Takuya, Yamamoto, Keiko, Horimoto, Hiromasa, Kobayashi, Tomoe, Yokoo, Hideki, Matsushita, Michiaki, Todo, Satoru, Asaka, Masahiro
Format Journal Article
LanguageEnglish
Published Japan Japan : Springer Japan 01.09.2009
Springer Japan
Springer Nature B.V
Subjects
Abdominal Surgery
Antiviral Agents - therapeutic use
Biliary Tract
Carcinoma, Hepatocellular - physiopathology
Carcinoma, Hepatocellular - therapy
Carcinoma, Hepatocellular - virology
Catheter Ablation
Colorectal Surgery
DNA, Viral - blood
Female
Follow-Up Studies
Gastroenterology
Hepatitis B - complications
Hepatitis B virus - genetics
Hepatology
Humans
Liver Neoplasms - physiopathology
Liver Neoplasms - therapy
Liver Neoplasms - virology
Male
Medicine
Medicine & Public Health
Middle Aged
Multivariate Analysis
Neoplasm Recurrence, Local
Original Article—Liver
Pancreas
Retrospective Studies
Risk Factors
Surgical Oncology
Recurrence
Hepatocellular carcinoma
Antiviral therapy
Hepatitis B virus
Online AccessGet full text

Cover

Abstract Background Prediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We investigated whether HBV DNA level and antiviral therapy are associated with HCC recurrence. Methods This retrospective study involved 103 patients who underwent hepatic resection or radiofrequency ablation for initial HCC. Patients were divided into four groups. Thirty had high serum HBV DNA levels (>4 log₁₀ copies/mL) and had not received antiviral therapy (high virus group; HVG). Thirty-four had low HBV DNA levels (<=4 log₁₀ copies/mL) and had not received antiviral therapy (low virus group; LVG). Twenty received antiviral therapy after HCC developed (therapeutic group A, TG-A). Nineteen received antiviral therapy before HCC developed (therapeutic group B, TG-B). Results Cumulative HCC recurrence rates at 3 years in the HVG, LVG, TG-B, and TG-A were 71.1%, 42.2%, 42.3%, and 52.0%, respectively. Recurrence rates differed significantly between the HVG and LVG (P = 0.016) and between the HVG and TG-B (P = 0.008). Recurrence rate in the TG-A was marginally lower than in the HVG (P = 0.10). On multivariate analysis, high serum hepatitis B virus DNA levels (hazard ratio: HR 2.67; 95% CI 1.31-5.47; P = 0.007) and absence of antiviral therapy (HR 2.57; 95% CI 1.34-4.94; P = 0.005) were independent risk factors for hepatocellular carcinoma recurrence. Conclusion HBV DNA level and antiviral therapy are associated with HCC recurrence. For patients with high HBV DNA levels, antiviral therapy before the development of HCC is important for prevention of recurrence.
AbstractList Prediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We investigated whether HBV DNA level and antiviral therapy are associated with HCC recurrence. This retrospective study involved 103 patients who underwent hepatic resection or radiofrequency ablation for initial HCC. Patients were divided into four groups. Thirty had high serum HBV DNA levels (>4 log10 copies/mL) and had not received antiviral therapy (high virus group; HVG). Thirty-four had low HBV DNA levels (≤4 log10 copies/mL) and had not received antiviral therapy (low virus group; LVG). Twenty received antiviral therapy after HCC developed (therapeutic group A, TG-A). Nineteen received antiviral therapy before HCC developed (therapeutic group B, TG-B). Cumulative HCC recurrence rates at 3 years in the HVG, LVG, TG-B, and TG-A were 71.1%, 42.2%, 42.3%, and 52.0%, respectively. Recurrence rates differed significantly between the HVG and LVG (P = 0.016) and between the HVG and TG-B (P = 0.008). Recurrence rate in the TG-A was marginally lower than in the HVG (P = 0.10). On multivariate analysis, high serum hepatitis B virus DNA levels (hazard ratio: HR 2.67; 95% CI 1.31-5.47; P = 0.007) and absence of antiviral therapy (HR 2.57; 95% CI 1.34-4.94; P = 0.005) were independent risk factors for hepatocellular carcinoma recurrence. HBV DNA level and antiviral therapy are associated with HCC recurrence. For patients with high HBV DNA levels, antiviral therapy before the development of HCC is important for prevention of recurrence.
Background Prediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We investigated whether HBV DNA level and antiviral therapy are associated with HCC recurrence. Methods This retrospective study involved 103 patients who underwent hepatic resection or radiofrequency ablation for initial HCC. Patients were divided into four groups. Thirty had high serum HBV DNA levels (>4 log 10  copies/mL) and had not received antiviral therapy (high virus group; HVG). Thirty-four had low HBV DNA levels (≤4 log 10  copies/mL) and had not received antiviral therapy (low virus group; LVG). Twenty received antiviral therapy after HCC developed (therapeutic group A, TG-A). Nineteen received antiviral therapy before HCC developed (therapeutic group B, TG-B). Results Cumulative HCC recurrence rates at 3 years in the HVG, LVG, TG-B, and TG-A were 71.1%, 42.2%, 42.3%, and 52.0%, respectively. Recurrence rates differed significantly between the HVG and LVG ( P  = 0.016) and between the HVG and TG-B ( P  = 0.008). Recurrence rate in the TG-A was marginally lower than in the HVG ( P  = 0.10). On multivariate analysis, high serum hepatitis B virus DNA levels (hazard ratio: HR 2.67; 95% CI 1.31–5.47; P  = 0.007) and absence of antiviral therapy (HR 2.57; 95% CI 1.34–4.94; P  = 0.005) were independent risk factors for hepatocellular carcinoma recurrence. Conclusion HBV DNA level and antiviral therapy are associated with HCC recurrence. For patients with high HBV DNA levels, antiviral therapy before the development of HCC is important for prevention of recurrence.
Prediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We investigated whether HBV DNA level and antiviral therapy are associated with HCC recurrence. This retrospective study involved 103 patients who underwent hepatic resection or radiofrequency ablation for initial HCC. Patients were divided into four groups. Thirty had high serum HBV DNA levels (>4 log(10) copies/mL) and had not received antiviral therapy (high virus group; HVG). Thirty-four had low HBV DNA levels (< or =4 log(10) copies/mL) and had not received antiviral therapy (low virus group; LVG). Twenty received antiviral therapy after HCC developed (therapeutic group A, TG-A). Nineteen received antiviral therapy before HCC developed (therapeutic group B, TG-B). Cumulative HCC recurrence rates at 3 years in the HVG, LVG, TG-B, and TG-A were 71.1%, 42.2%, 42.3%, and 52.0%, respectively. Recurrence rates differed significantly between the HVG and LVG (P = 0.016) and between the HVG and TG-B (P = 0.008). Recurrence rate in the TG-A was marginally lower than in the HVG (P = 0.10). On multivariate analysis, high serum hepatitis B virus DNA levels (hazard ratio: HR 2.67; 95% CI 1.31-5.47; P = 0.007) and absence of antiviral therapy (HR 2.57; 95% CI 1.34-4.94; P = 0.005) were independent risk factors for hepatocellular carcinoma recurrence. HBV DNA level and antiviral therapy are associated with HCC recurrence. For patients with high HBV DNA levels, antiviral therapy before the development of HCC is important for prevention of recurrence.
Background Prediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We investigated whether HBV DNA level and antiviral therapy are associated with HCC recurrence. Methods This retrospective study involved 103 patients who underwent hepatic resection or radiofrequency ablation for initial HCC. Patients were divided into four groups. Thirty had high serum HBV DNA levels (>4 log1† copies/mL) and had not received antiviral therapy (high virus group; HVG). Thirty-four had low HBV DNA levels (<=4 log1† copies/mL) and had not received antiviral therapy (low virus group; LVG). Twenty received antiviral therapy after HCC developed (therapeutic group A, TG-A). Nineteen received antiviral therapy before HCC developed (therapeutic group B, TG-B). Results Cumulative HCC recurrence rates at 3 years in the HVG, LVG, TG-B, and TG-A were 71.1%, 42.2%, 42.3%, and 52.0%, respectively. Recurrence rates differed significantly between the HVG and LVG (P = 0.016) and between the HVG and TG-B (P = 0.008). Recurrence rate in the TG-A was marginally lower than in the HVG (P = 0.10). On multivariate analysis, high serum hepatitis B virus DNA levels (hazard ratio: HR 2.67; 95% CI 1.31-5.47; P = 0.007) and absence of antiviral therapy (HR 2.57; 95% CI 1.34-4.94; P = 0.005) were independent risk factors for hepatocellular carcinoma recurrence. Conclusion HBV DNA level and antiviral therapy are associated with HCC recurrence. For patients with high HBV DNA levels, antiviral therapy before the development of HCC is important for prevention of recurrence.
Background Prediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We investigated whether HBV DNA level and antiviral therapy are associated with HCC recurrence. Methods This retrospective study involved 103 patients who underwent hepatic resection or radiofrequency ablation for initial HCC. Patients were divided into four groups. Thirty had high serum HBV DNA levels (>4 log₁₀ copies/mL) and had not received antiviral therapy (high virus group; HVG). Thirty-four had low HBV DNA levels (<=4 log₁₀ copies/mL) and had not received antiviral therapy (low virus group; LVG). Twenty received antiviral therapy after HCC developed (therapeutic group A, TG-A). Nineteen received antiviral therapy before HCC developed (therapeutic group B, TG-B). Results Cumulative HCC recurrence rates at 3 years in the HVG, LVG, TG-B, and TG-A were 71.1%, 42.2%, 42.3%, and 52.0%, respectively. Recurrence rates differed significantly between the HVG and LVG (P = 0.016) and between the HVG and TG-B (P = 0.008). Recurrence rate in the TG-A was marginally lower than in the HVG (P = 0.10). On multivariate analysis, high serum hepatitis B virus DNA levels (hazard ratio: HR 2.67; 95% CI 1.31-5.47; P = 0.007) and absence of antiviral therapy (HR 2.57; 95% CI 1.34-4.94; P = 0.005) were independent risk factors for hepatocellular carcinoma recurrence. Conclusion HBV DNA level and antiviral therapy are associated with HCC recurrence. For patients with high HBV DNA levels, antiviral therapy before the development of HCC is important for prevention of recurrence.
Prediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We investigated whether HBV DNA level and antiviral therapy are associated with HCC recurrence.BACKGROUNDPrediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We investigated whether HBV DNA level and antiviral therapy are associated with HCC recurrence.This retrospective study involved 103 patients who underwent hepatic resection or radiofrequency ablation for initial HCC. Patients were divided into four groups. Thirty had high serum HBV DNA levels (>4 log(10) copies/mL) and had not received antiviral therapy (high virus group; HVG). Thirty-four had low HBV DNA levels (< or =4 log(10) copies/mL) and had not received antiviral therapy (low virus group; LVG). Twenty received antiviral therapy after HCC developed (therapeutic group A, TG-A). Nineteen received antiviral therapy before HCC developed (therapeutic group B, TG-B).METHODSThis retrospective study involved 103 patients who underwent hepatic resection or radiofrequency ablation for initial HCC. Patients were divided into four groups. Thirty had high serum HBV DNA levels (>4 log(10) copies/mL) and had not received antiviral therapy (high virus group; HVG). Thirty-four had low HBV DNA levels (< or =4 log(10) copies/mL) and had not received antiviral therapy (low virus group; LVG). Twenty received antiviral therapy after HCC developed (therapeutic group A, TG-A). Nineteen received antiviral therapy before HCC developed (therapeutic group B, TG-B).Cumulative HCC recurrence rates at 3 years in the HVG, LVG, TG-B, and TG-A were 71.1%, 42.2%, 42.3%, and 52.0%, respectively. Recurrence rates differed significantly between the HVG and LVG (P = 0.016) and between the HVG and TG-B (P = 0.008). Recurrence rate in the TG-A was marginally lower than in the HVG (P = 0.10). On multivariate analysis, high serum hepatitis B virus DNA levels (hazard ratio: HR 2.67; 95% CI 1.31-5.47; P = 0.007) and absence of antiviral therapy (HR 2.57; 95% CI 1.34-4.94; P = 0.005) were independent risk factors for hepatocellular carcinoma recurrence.RESULTSCumulative HCC recurrence rates at 3 years in the HVG, LVG, TG-B, and TG-A were 71.1%, 42.2%, 42.3%, and 52.0%, respectively. Recurrence rates differed significantly between the HVG and LVG (P = 0.016) and between the HVG and TG-B (P = 0.008). Recurrence rate in the TG-A was marginally lower than in the HVG (P = 0.10). On multivariate analysis, high serum hepatitis B virus DNA levels (hazard ratio: HR 2.67; 95% CI 1.31-5.47; P = 0.007) and absence of antiviral therapy (HR 2.57; 95% CI 1.34-4.94; P = 0.005) were independent risk factors for hepatocellular carcinoma recurrence.HBV DNA level and antiviral therapy are associated with HCC recurrence. For patients with high HBV DNA levels, antiviral therapy before the development of HCC is important for prevention of recurrence.CONCLUSIONHBV DNA level and antiviral therapy are associated with HCC recurrence. For patients with high HBV DNA levels, antiviral therapy before the development of HCC is important for prevention of recurrence.
Author Nakanishi, Mitsuru
Kohara, Toshihisa
Hige, Shuhei
Yamamoto, Keiko
Matsushita, Michiaki
Yamamoto, Yoshiya
Sho, Takuya
Nakanishi, Kazuaki
Chuma, Makoto
Nagasaka, Atsushi
Yokoo, Hideki
Asaka, Masahiro
Meguro, Takashi
Kobayashi, Tomoe
Todo, Satoru
Kamiyama, Toshiya
Horimoto, Hiromasa
Author_xml – sequence: 1
  fullname: Chuma, Makoto
– sequence: 2
  fullname: Hige, Shuhei
– sequence: 3
  fullname: Kamiyama, Toshiya
– sequence: 4
  fullname: Meguro, Takashi
– sequence: 5
  fullname: Nagasaka, Atsushi
– sequence: 6
  fullname: Nakanishi, Kazuaki
– sequence: 7
  fullname: Yamamoto, Yoshiya
– sequence: 8
  fullname: Nakanishi, Mitsuru
– sequence: 9
  fullname: Kohara, Toshihisa
– sequence: 10
  fullname: Sho, Takuya
– sequence: 11
  fullname: Yamamoto, Keiko
– sequence: 12
  fullname: Horimoto, Hiromasa
– sequence: 13
  fullname: Kobayashi, Tomoe
– sequence: 14
  fullname: Yokoo, Hideki
– sequence: 15
  fullname: Matsushita, Michiaki
– sequence: 16
  fullname: Todo, Satoru
– sequence: 17
  fullname: Asaka, Masahiro
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19554391$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1v1DAQhi1URLeFH8AFLA5wCowTf2yObfmUKjhAz5bXmXRdZe3Fdha1_6L_uE5TQOphDyOP7Od9x57xETnwwSMhLxm8ZwDqQwIQjagA2ima6uYJWTBedkRb1wdkAS3nFWOKH5KjlK4AWANi-YwcslYI3rRsQW6d74cRvUUaerrGrckuu0RP6cfvJ3TAHQ7U-K5EdjsXzUDzGqPZXtPgaUQ7xngvNn3GSJ0v4sKU7eKzQ5ojmrxBn8sRnbxLmugfl9dzrWBxGMbBRGpNtM6HjXlOnvZmSPjiYT0mF58__Tr7Wp3_-PLt7OS8skK0uTJccAsorDJgWo7tSqw6yblqmlpaVcuVkAokGiNXyw5gKZedhUbZngvWlW4dk3ez7zaG3yOmrDcuTdcxHsOYtGo4CBC8LuTbvSSXHFireAHfPAKvwhh9eYWumWJSwn3dVw_QuNpgp7fRbUy81n9nUgA1AzaGlCL22rpcWhd8jsYNmoGepq_n6eviOUWjb4qSPVL-M9-jqWdNKqy_xPj_zvtEr2dRb4I2l9ElffGznr4Xk0umSnIHNKLMcQ
CitedBy_id crossref_primary_10_1186_1477_7819_11_52
crossref_primary_10_1097_SLA_0000000000000858
crossref_primary_10_3109_00365521_2013_871745
crossref_primary_10_1109_JBHI_2014_2357719
crossref_primary_10_4103_jcrt_jcrt_291_21
crossref_primary_10_1097_SLA_0000000000001229
crossref_primary_10_1111_j_1440_1746_2011_06950_x
crossref_primary_10_3892_mco_2015_614
crossref_primary_10_1002_14651858_CD014869_pub2
crossref_primary_10_31586_Cancers_0403_03
crossref_primary_10_1111_jgh_12917
crossref_primary_10_1371_journal_pone_0102761
crossref_primary_10_1002_hep_28266
crossref_primary_10_1055_s_0034_1394141
crossref_primary_10_1002_ijc_25382
crossref_primary_10_1111_j_1440_1746_2010_06416_x
crossref_primary_10_1111_j_1365_2036_2011_04634_x
crossref_primary_10_1016_j_canlet_2012_03_011
crossref_primary_10_1517_14656566_2016_1149165
crossref_primary_10_1016_j_amjsurg_2019_05_016
crossref_primary_10_1080_17474124_2017_1361822
crossref_primary_10_1016_j_ejso_2013_03_020
crossref_primary_10_1097_MD_0000000000014070
crossref_primary_10_1111_j_1440_1746_2011_06777_x
crossref_primary_10_1016_j_jfma_2017_09_007
crossref_primary_10_1200_JCO_2012_48_5896
crossref_primary_10_1080_08941939_2019_1586015
crossref_primary_10_1007_s10620_018_5252_8
crossref_primary_10_3389_fmicb_2021_665201
crossref_primary_10_1128_JCM_00731_10
crossref_primary_10_1016_j_ijid_2017_09_003
crossref_primary_10_1007_s00270_016_1462_7
crossref_primary_10_1245_s10434_013_3046_y
crossref_primary_10_1002_14651858_CD014869
crossref_primary_10_1186_s40880_016_0089_z
crossref_primary_10_1016_j_jvir_2011_11_012
crossref_primary_10_1245_s10434_012_2803_7
crossref_primary_10_1016_j_jfma_2011_02_002
crossref_primary_10_1111_j_1478_3231_2011_02634_x
crossref_primary_10_4254_wjh_v6_i9_652
crossref_primary_10_1155_2016_5234969
crossref_primary_10_1007_s13277_014_2443_6
crossref_primary_10_1111_j_1399_0012_2010_01349_x
crossref_primary_10_1245_s10434_013_3320_z
crossref_primary_10_4254_wjh_v7_i13_1742
crossref_primary_10_1111_jgh_12472
crossref_primary_10_1007_s11845_014_1164_6
crossref_primary_10_1007_s00535_012_0690_0
crossref_primary_10_1136_esmoopen_2016_000042
crossref_primary_10_1016_j_crad_2015_06_092
crossref_primary_10_1007_s12072_016_9720_y
crossref_primary_10_1148_radiol_13121498
crossref_primary_10_1097_MD_0000000000009377
crossref_primary_10_1016_j_ejso_2012_04_010
crossref_primary_10_1111_hepr_12584
crossref_primary_10_3748_wjg_v25_i28_3704
crossref_primary_10_1007_s13277_014_2881_1
crossref_primary_10_18632_oncotarget_10335
crossref_primary_10_1016_S1499_3872_13_60041_7
crossref_primary_10_1148_radiol_11110817
crossref_primary_10_1021_acsinfecdis_4c00514
crossref_primary_10_1016_j_canlet_2015_07_016
crossref_primary_10_1159_000518837
crossref_primary_10_3390_cancers13236009
crossref_primary_10_1002_14651858_CD008713_pub2
crossref_primary_10_1111_hepr_12172
crossref_primary_10_1016_j_mehy_2010_12_016
crossref_primary_10_1016_j_gendis_2020_02_001
crossref_primary_10_3748_wjg_v21_i27_8249
crossref_primary_10_1111_jvh_12717
crossref_primary_10_1186_s40880_017_0183_x
crossref_primary_10_3748_wjg_v27_i29_4831
crossref_primary_10_1007_s00534_011_0489_z
crossref_primary_10_3390_diseases6020027
crossref_primary_10_1111_jvh_12036
crossref_primary_10_1016_j_clinre_2014_12_003
crossref_primary_10_1111_j_1872_034X_2012_01079_x
crossref_primary_10_1111_j_1440_1746_2010_06516_x
Cites_doi 10.1053/j.gastro.2004.09.039
10.1099/vir.0.19650-0
10.1093/carcin/bgn090
10.1002/1097-0142(20000801)89:3<500::AID-CNCR4>3.0.CO;2-O
10.1056/NEJMoa033364
10.1002/hep.20933
10.1038/351317a0
10.1053/j.gastro.2008.02.013
10.1002/jmv.21117
10.1016/j.hepres.2005.02.006
10.1053/j.gastro.2003.10.051
10.1053/j.gastro.2005.06.055
10.1053/jhep.2000.20237
10.3322/canjclin.55.2.74
10.1016/0016-5085(95)90450-6
10.1111/j.1572-0241.2008.01872.x
10.1002/hep.21933
10.1053/gast.2003.50013
10.1016/S0923-2516(99)89003-7
10.1016/j.antiviral.2003.08.010
10.1056/NEJM199512213332501
10.1053/gast.2002.33411
10.1097/01.sla.0000225126.56483.b3
10.1002/cncr.22984
10.1053/j.gastro.2005.04.009
10.1097/MCG.0b013e3180ebe790
10.1200/JCO.2000.18.5.1094
10.1111/j.1872-034X.2007.00013.x
ContentType Journal Article
Copyright Springer 2009
Copyright_xml – notice: Springer 2009
DBID FBQ
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7T5
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
FYUFA
GHDGH
H94
K9-
K9.
KB0
M0R
M0S
M1P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7S9
L.6
7X8
DOI 10.1007/s00535-009-0093-z
DatabaseName AGRIS
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Consumer Health Database
ProQuest Health & Medical Collection
Medical Database
ProQuest Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
AGRICOLA
AGRICOLA - Academic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
AGRICOLA
AGRICOLA - Academic
MEDLINE - Academic
DatabaseTitleList ProQuest One Academic Middle East (New)

MEDLINE
AGRICOLA

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
– sequence: 4
  dbid: FBQ
  name: AGRIS
  url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1435-5922
EndPage 999
ExternalDocumentID 1862216191
19554391
10_1007_s00535_009_0093_z
US201301681701
Genre Journal Article
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.55
.86
.GJ
.VR
06C
06D
0R~
0VY
199
1N0
2.D
203
28-
29K
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3O-
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5VS
67Z
6NX
78A
7RV
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AABYN
AAFGU
AAHNG
AAIAL
AAJKR
AAKSU
AANXM
AANZL
AARHV
AARTL
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYFA
AAYIU
AAYQN
AAYTO
ABBBX
ABBXA
ABDZT
ABECU
ABFGW
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKAS
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABPTK
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACBMV
ACBRV
ACBXY
ACBYP
ACGFS
ACHSB
ACHXU
ACIGE
ACIPQ
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPRK
ACTTH
ACUDM
ACVWB
ACWMK
ADBBV
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADMDM
ADOXG
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEEQQ
AEFIE
AEFTE
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AENEX
AEOHA
AEPYU
AEQTP
AESKC
AESTI
AETLH
AEVLU
AEVTX
AEXYK
AFAFS
AFEXP
AFKRA
AFLOW
AFNRJ
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGBP
AGGDS
AGJBK
AGKHE
AGMZJ
AGQMX
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIIXL
AILAN
AIMYW
AITGF
AJBLW
AJDOV
AJRNO
AJZVZ
AKMHD
AKQUC
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AOCGG
ARMRJ
AXYYD
AZFZN
AZQEC
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BKEYQ
BKNYI
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
D-I
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
EX3
F5P
FBQ
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IAO
IHE
IHR
IJ-
IKXTQ
IMOTQ
INH
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
K9-
KDC
KOV
KOW
KPH
LAS
LLZTM
M0R
M1P
M4Y
MA-
N2Q
N9A
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
P2P
P9S
PCD
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R89
R9I
RHV
RIG
RNI
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UNUBA
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
WOW
X7M
YLTOR
Z45
Z7U
Z7W
Z7X
Z82
Z83
Z87
Z8O
Z8Q
Z8V
Z8W
Z91
ZMTXR
ZOVNA
~EX
~KM
AACDK
AAJBT
AASML
AAYZH
ABAKF
ABQSL
ACAOD
ACDTI
ACPIV
ACZOJ
AEFQL
AEMSY
AFBBN
AGQEE
AGRTI
AIGIU
ALIPV
BSONS
H13
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
7T5
7XB
8FK
H94
K9.
PKEHL
PQEST
PQUKI
7S9
L.6
PUEGO
7X8
ID FETCH-LOGICAL-c559t-a454c0e5c7a0a94e9b5bd64473326c726b56706eaa6b8d00868dc037cf451d093
IEDL.DBID U2A
ISSN 0944-1174
1435-5922
IngestDate Thu Jul 10 19:02:27 EDT 2025
Sun Aug 24 03:58:11 EDT 2025
Sat Aug 23 13:55:04 EDT 2025
Mon Jul 21 05:29:17 EDT 2025
Tue Jul 01 04:34:04 EDT 2025
Thu Apr 24 22:49:10 EDT 2025
Fri Feb 21 02:29:31 EST 2025
Wed Dec 27 18:36:06 EST 2023
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords Recurrence
Hepatocellular carcinoma
Antiviral therapy
Hepatitis B virus
Language English
License http://www.springer.com/tdm
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c559t-a454c0e5c7a0a94e9b5bd64473326c726b56706eaa6b8d00868dc037cf451d093
Notes http://dx.doi.org/10.1007/s00535-009-0093-z
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://hdl.handle.net/2115/39478
PMID 19554391
PQID 217166009
PQPubID 33411
PageCount 9
ParticipantIDs proquest_miscellaneous_734050542
proquest_miscellaneous_46401974
proquest_journals_217166009
pubmed_primary_19554391
crossref_citationtrail_10_1007_s00535_009_0093_z
crossref_primary_10_1007_s00535_009_0093_z
springer_journals_10_1007_s00535_009_0093_z
fao_agris_US201301681701
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2009-09-01
PublicationDateYYYYMMDD 2009-09-01
PublicationDate_xml – month: 09
  year: 2009
  text: 2009-09-01
  day: 01
PublicationDecade 2000
PublicationPlace Japan
PublicationPlace_xml – name: Japan
– name: Tokyo
PublicationTitle Journal of gastroenterology
PublicationTitleAbbrev J Gastroenterol
PublicationTitleAlternate J Gastroenterol
PublicationYear 2009
Publisher Japan : Springer Japan
Springer Japan
Springer Nature B.V
Publisher_xml – name: Japan : Springer Japan
– name: Springer Japan
– name: Springer Nature B.V
References Livraghi, Meloni, Di Stasi, Rolle, Solbiati, Tinelli (CR6) 2008; 47
Adachi, Maeda, Matsumata, Shirabe, Kinukawa, Sugimachi (CR9) 1995; 108
Huang, Wang, An, Zhou, Zhou, Chan (CR15) 2008; 80
Yoon, Chang, Ahn, Kim, Park, Kang (CR28) 2008; 29
Wang, Gibson, Vermeulen, Yeh, Forrester, Stürzbecher (CR27) 1995; 55
Befeler, Di Bisceglie (CR2) 2002; 122
Ioannou, Perkins, Carithers (CR4) 2008; 134
Liaw, Sung, Chow, Farrell, Lee, Yuen (CR18) 2004; 351
Dienstag, Goldin, Heathcote, Hann, Woessner, Stephenson (CR17) 2003; 124
Chang, Gish, Hadziyannis, Cianciara, Rizzetto, Schiff (CR21) 2005; 129
Koike, Shiratori, Sato, Obi, Teratani, Imamura (CR10) 2000; 32
Pan, Clayton, Feitelson (CR30) 2004; 85
Shiina, Teratani, Obi, Sato, Tateishi, Fujishima (CR5) 2005; 129
Peters, Hann, Martin, Heathcote, Buggisch, Rubin (CR20) 2004; 126
Kubo, Tanaka, Takemura, Yamamoto, Hai, Ichikawa (CR22) 2007; 37
Kim, Koike, Saito, Miyamura, Jay (CR25) 1991; 351
Dienstag, Perrillo, Schiff, Bartholomew, Vicary, Rubin (CR16) 1995; 333
Poon, Fan, Ng, Lo, Liu, Wong (CR12) 2000; 89
Colombo, Sangiovanni (CR29) 2003; 60
Song, Ip, Fong (CR3) 2004; 127
Jang, Choi, Bae, Yoon, Woo, Chang (CR14) 2007; 110
Hung, Poon, Lai, Fung, Fan, Yuen (CR13) 2008; 103
Sasaki, Yamada, Tanaka, Ohigashi, Eguchi, Yano (CR11) 2006; 244
Parkin, Bray, Ferlay, Pisani (CR1) 2005; 55
Poon, Fan, Lo, Liu, Ng, Wong (CR7) 2000; 18
Paterlini, Poussin, Kew, Franco, Brechot (CR26) 1995; 21
Matsumoto, Tanaka, Rokuhara, Kiyosawa, Kumada, Omata (CR19) 2005; 32
Toyama, Hiramatsu, Yakushijin, Oze, Nakanishi, Yasumaru (CR8) 2008; 42
Kew (CR24) 1998; 149
Bruix, Sherman (CR23) 2005; 42
S Shiina (93_CR5) 2005; 129
E Adachi (93_CR9) 1995; 108
DM Parkin (93_CR1) 2005; 55
Y Sasaki (93_CR11) 2006; 244
T Livraghi (93_CR6) 2008; 47
JL Dienstag (93_CR17) 2003; 124
YF Liaw (93_CR18) 2004; 351
J Bruix (93_CR23) 2005; 42
RT Poon (93_CR7) 2000; 18
MC Kew (93_CR24) 1998; 149
P Paterlini (93_CR26) 1995; 21
MG Peters (93_CR20) 2004; 126
Y Koike (93_CR10) 2000; 32
IF Hung (93_CR13) 2008; 103
GN Ioannou (93_CR4) 2008; 134
JW Jang (93_CR14) 2007; 110
TT Chang (93_CR21) 2005; 129
T Toyama (93_CR8) 2008; 42
JL Dienstag (93_CR16) 1995; 333
CM Kim (93_CR25) 1991; 351
YJ Yoon (93_CR28) 2008; 29
XW Wang (93_CR27) 1995; 55
M Colombo (93_CR29) 2003; 60
J Pan (93_CR30) 2004; 85
Y Huang (93_CR15) 2008; 80
A Matsumoto (93_CR19) 2005; 32
S Kubo (93_CR22) 2007; 37
TJ Song (93_CR3) 2004; 127
RT Poon (93_CR12) 2000; 89
AS Befeler (93_CR2) 2002; 122
11093727 - Hepatology. 2000 Dec;32(6):1216-23
7875479 - Gastroenterology. 1995 Mar;108(3):768-75
14769885 - J Gen Virol. 2004 Feb;85(Pt 2):275-82
17060771 - Ann Surg. 2006 Nov;244(5):771-80
15470215 - N Engl J Med. 2004 Oct 7;351(15):1521-31
16012942 - Gastroenterology. 2005 Jul;129(1):122-30
15508091 - Gastroenterology. 2004 Nov;127(5 Suppl 1):S248-60
18008357 - Hepatology. 2008 Jan;47(1):82-9
12512035 - Gastroenterology. 2003 Jan;124(1):105-17
18390844 - Carcinogenesis. 2008 Jun;29(6):1192-6
17300703 - Hepatol Res. 2007 Feb;37(2):94-100
2034275 - Nature. 1991 May 23;351(6324):317-20
9879602 - Res Virol. 1998 Sep-Oct;149(5):257-62
14699491 - Gastroenterology. 2004 Jan;126(1):91-101
18471511 - Gastroenterology. 2008 May;134(5):1342-51
16230074 - Gastroenterology. 2005 Oct;129(4):1198-209
17724708 - Cancer. 2007 Oct 15;110(8):1760-7
16250051 - Hepatology. 2005 Nov;42(5):1208-36
15761078 - CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
8521383 - Cancer Res. 1995 Dec 15;55(24):6012-6
7477217 - N Engl J Med. 1995 Dec 21;333(25):1657-61
10694562 - J Clin Oncol. 2000 Mar;18(5):1094-101
18616655 - Am J Gastroenterol. 2008 Jul;103(7):1663-73
18297705 - J Med Virol. 2008 Apr;80(4):591-7
16024289 - Hepatol Res. 2005 Jul;32(3):173-84
14638411 - Antiviral Res. 2003 Oct;60(2):145-50
18223490 - J Clin Gastroenterol. 2008 Mar;42(3):317-22
12016426 - Gastroenterology. 2002 May;122(6):1609-19
10931448 - Cancer. 2000 Aug 1;89(3):500-7
7843699 - Hepatology. 1995 Feb;21(2):313-21
References_xml – volume: 55
  start-page: 6012
  year: 1995
  end-page: 6016
  ident: CR27
  article-title: Abrogation of p53-induced apoptosis by the hepatitis B virus X gene
  publication-title: Cancer Res
– volume: 127
  start-page: S248
  year: 2004
  end-page: S260
  ident: CR3
  article-title: Hepatocellular carcinoma: current surgical management
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2004.09.039
– volume: 85
  start-page: 275
  year: 2004
  end-page: 282
  ident: CR30
  article-title: Hepatitis B virus X antigen promotes transforming growth factor-beta1 (TGF-beta1) activity by up-regulation of TGF-beta1 and down-regulation of alpha2-macroglobulin
  publication-title: J Gen Virol
  doi: 10.1099/vir.0.19650-0
– volume: 29
  start-page: 1192
  year: 2008
  end-page: 1196
  ident: CR28
  article-title: MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgn090
– volume: 21
  start-page: 313
  year: 1995
  end-page: 321
  ident: CR26
  article-title: Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma
  publication-title: Hepatology
– volume: 89
  start-page: 500
  year: 2000
  end-page: 507
  ident: CR12
  article-title: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma
  publication-title: Cancer
  doi: 10.1002/1097-0142(20000801)89:3<500::AID-CNCR4>3.0.CO;2-O
– volume: 351
  start-page: 1521
  year: 2004
  end-page: 1531
  ident: CR18
  article-title: Lamivudine for patients with chronic hepatitis B and advanced disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa033364
– volume: 42
  start-page: 1208
  year: 2005
  end-page: 1236
  ident: CR23
  article-title: Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1002/hep.20933
– volume: 351
  start-page: 317
  year: 1991
  end-page: 320
  ident: CR25
  article-title: HBx gene of hepatitis B virus induces liver cancer in transgenic mice
  publication-title: Nature
  doi: 10.1038/351317a0
– volume: 134
  start-page: 1342
  year: 2008
  end-page: 1351
  ident: CR4
  article-title: Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2008.02.013
– volume: 80
  start-page: 591
  year: 2008
  end-page: 597
  ident: CR15
  article-title: Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma
  publication-title: J Med Virol
  doi: 10.1002/jmv.21117
– volume: 32
  start-page: 173
  year: 2005
  end-page: 184
  ident: CR19
  article-title: Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients
  publication-title: Hepatol Res
  doi: 10.1016/j.hepres.2005.02.006
– volume: 126
  start-page: 91
  year: 2004
  end-page: 101
  ident: CR20
  article-title: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2003.10.051
– volume: 129
  start-page: 1198
  year: 2005
  end-page: 1209
  ident: CR21
  article-title: A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2005.06.055
– volume: 32
  start-page: 1216
  year: 2000
  end-page: 1223
  ident: CR10
  article-title: Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus—an analysis of 236 consecutive patients with a single lesion
  publication-title: Hepatology
  doi: 10.1053/jhep.2000.20237
– volume: 55
  start-page: 74
  year: 2005
  end-page: 108
  ident: CR1
  article-title: Global cancer statistics, 2002
  publication-title: CA Cancer J Clin
  doi: 10.3322/canjclin.55.2.74
– volume: 108
  start-page: 768
  year: 1995
  end-page: 775
  ident: CR9
  article-title: Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma
  publication-title: Gastroenterology
  doi: 10.1016/0016-5085(95)90450-6
– volume: 103
  start-page: 1663
  year: 2008
  end-page: 1673
  ident: CR13
  article-title: Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2008.01872.x
– volume: 47
  start-page: 82
  year: 2008
  end-page: 89
  ident: CR6
  article-title: Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?
  publication-title: Hepatology
  doi: 10.1002/hep.21933
– volume: 124
  start-page: 105
  year: 2003
  end-page: 117
  ident: CR17
  article-title: Histological outcome during long-term lamivudine therapy
  publication-title: Gastroenterology
  doi: 10.1053/gast.2003.50013
– volume: 42
  start-page: 317
  year: 2008
  end-page: 322
  ident: CR8
  article-title: A new prognostic system for hepatocellular carcinoma including recurrent cases: a study of 861 patients in a single institution
  publication-title: J Clin Gastroenterol
– volume: 149
  start-page: 257
  year: 1998
  end-page: 262
  ident: CR24
  article-title: Hepatitis viruses and hepatocellular carcinoma
  publication-title: Res Virol
  doi: 10.1016/S0923-2516(99)89003-7
– volume: 60
  start-page: 145
  year: 2003
  end-page: 150
  ident: CR29
  article-title: Etiology, natural history and treatment of hepatocellular carcinoma
  publication-title: Antiviral Res
  doi: 10.1016/j.antiviral.2003.08.010
– volume: 333
  start-page: 1657
  year: 1995
  end-page: 1661
  ident: CR16
  article-title: A preliminary trial of lamivudine for chronic hepatitis B infection
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199512213332501
– volume: 122
  start-page: 1609
  year: 2002
  end-page: 1619
  ident: CR2
  article-title: Hepatocellular carcinoma: diagnosis and treatment
  publication-title: Gastroenterology
  doi: 10.1053/gast.2002.33411
– volume: 37
  start-page: 94
  year: 2007
  end-page: 100
  ident: CR22
  article-title: Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus
  publication-title: Hepatol Res
– volume: 18
  start-page: 1094
  year: 2000
  end-page: 1101
  ident: CR7
  article-title: Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis
  publication-title: J Clin Oncol
– volume: 244
  start-page: 771
  year: 2006
  end-page: 780
  ident: CR11
  article-title: Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma
  publication-title: Ann Surg
  doi: 10.1097/01.sla.0000225126.56483.b3
– volume: 110
  start-page: 1760
  year: 2007
  end-page: 1767
  ident: CR14
  article-title: The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence
  publication-title: Cancer
  doi: 10.1002/cncr.22984
– volume: 129
  start-page: 122
  year: 2005
  end-page: 130
  ident: CR5
  article-title: A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2005.04.009
– volume: 244
  start-page: 771
  year: 2006
  ident: 93_CR11
  publication-title: Ann Surg
  doi: 10.1097/01.sla.0000225126.56483.b3
– volume: 127
  start-page: S248
  year: 2004
  ident: 93_CR3
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2004.09.039
– volume: 134
  start-page: 1342
  year: 2008
  ident: 93_CR4
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2008.02.013
– volume: 42
  start-page: 317
  year: 2008
  ident: 93_CR8
  publication-title: J Clin Gastroenterol
  doi: 10.1097/MCG.0b013e3180ebe790
– volume: 42
  start-page: 1208
  year: 2005
  ident: 93_CR23
  publication-title: Hepatology
  doi: 10.1002/hep.20933
– volume: 55
  start-page: 74
  year: 2005
  ident: 93_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/canjclin.55.2.74
– volume: 108
  start-page: 768
  year: 1995
  ident: 93_CR9
  publication-title: Gastroenterology
  doi: 10.1016/0016-5085(95)90450-6
– volume: 85
  start-page: 275
  year: 2004
  ident: 93_CR30
  publication-title: J Gen Virol
  doi: 10.1099/vir.0.19650-0
– volume: 18
  start-page: 1094
  year: 2000
  ident: 93_CR7
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2000.18.5.1094
– volume: 89
  start-page: 500
  year: 2000
  ident: 93_CR12
  publication-title: Cancer
  doi: 10.1002/1097-0142(20000801)89:3<500::AID-CNCR4>3.0.CO;2-O
– volume: 60
  start-page: 145
  year: 2003
  ident: 93_CR29
  publication-title: Antiviral Res
  doi: 10.1016/j.antiviral.2003.08.010
– volume: 32
  start-page: 1216
  year: 2000
  ident: 93_CR10
  publication-title: Hepatology
  doi: 10.1053/jhep.2000.20237
– volume: 103
  start-page: 1663
  year: 2008
  ident: 93_CR13
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2008.01872.x
– volume: 149
  start-page: 257
  year: 1998
  ident: 93_CR24
  publication-title: Res Virol
  doi: 10.1016/S0923-2516(99)89003-7
– volume: 110
  start-page: 1760
  year: 2007
  ident: 93_CR14
  publication-title: Cancer
  doi: 10.1002/cncr.22984
– volume: 122
  start-page: 1609
  year: 2002
  ident: 93_CR2
  publication-title: Gastroenterology
  doi: 10.1053/gast.2002.33411
– volume: 21
  start-page: 313
  year: 1995
  ident: 93_CR26
  publication-title: Hepatology
– volume: 47
  start-page: 82
  year: 2008
  ident: 93_CR6
  publication-title: Hepatology
  doi: 10.1002/hep.21933
– volume: 126
  start-page: 91
  year: 2004
  ident: 93_CR20
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2003.10.051
– volume: 129
  start-page: 1198
  year: 2005
  ident: 93_CR21
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2005.06.055
– volume: 29
  start-page: 1192
  year: 2008
  ident: 93_CR28
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgn090
– volume: 80
  start-page: 591
  year: 2008
  ident: 93_CR15
  publication-title: J Med Virol
  doi: 10.1002/jmv.21117
– volume: 32
  start-page: 173
  year: 2005
  ident: 93_CR19
  publication-title: Hepatol Res
  doi: 10.1016/j.hepres.2005.02.006
– volume: 351
  start-page: 317
  year: 1991
  ident: 93_CR25
  publication-title: Nature
  doi: 10.1038/351317a0
– volume: 124
  start-page: 105
  year: 2003
  ident: 93_CR17
  publication-title: Gastroenterology
  doi: 10.1053/gast.2003.50013
– volume: 351
  start-page: 1521
  year: 2004
  ident: 93_CR18
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa033364
– volume: 55
  start-page: 6012
  year: 1995
  ident: 93_CR27
  publication-title: Cancer Res
– volume: 129
  start-page: 122
  year: 2005
  ident: 93_CR5
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2005.04.009
– volume: 333
  start-page: 1657
  year: 1995
  ident: 93_CR16
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199512213332501
– volume: 37
  start-page: 94
  year: 2007
  ident: 93_CR22
  publication-title: Hepatol Res
  doi: 10.1111/j.1872-034X.2007.00013.x
– reference: 15470215 - N Engl J Med. 2004 Oct 7;351(15):1521-31
– reference: 11093727 - Hepatology. 2000 Dec;32(6):1216-23
– reference: 7843699 - Hepatology. 1995 Feb;21(2):313-21
– reference: 16012942 - Gastroenterology. 2005 Jul;129(1):122-30
– reference: 15761078 - CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
– reference: 18471511 - Gastroenterology. 2008 May;134(5):1342-51
– reference: 14769885 - J Gen Virol. 2004 Feb;85(Pt 2):275-82
– reference: 17724708 - Cancer. 2007 Oct 15;110(8):1760-7
– reference: 18616655 - Am J Gastroenterol. 2008 Jul;103(7):1663-73
– reference: 16024289 - Hepatol Res. 2005 Jul;32(3):173-84
– reference: 10931448 - Cancer. 2000 Aug 1;89(3):500-7
– reference: 15508091 - Gastroenterology. 2004 Nov;127(5 Suppl 1):S248-60
– reference: 9879602 - Res Virol. 1998 Sep-Oct;149(5):257-62
– reference: 18008357 - Hepatology. 2008 Jan;47(1):82-9
– reference: 17300703 - Hepatol Res. 2007 Feb;37(2):94-100
– reference: 7477217 - N Engl J Med. 1995 Dec 21;333(25):1657-61
– reference: 10694562 - J Clin Oncol. 2000 Mar;18(5):1094-101
– reference: 12016426 - Gastroenterology. 2002 May;122(6):1609-19
– reference: 17060771 - Ann Surg. 2006 Nov;244(5):771-80
– reference: 16230074 - Gastroenterology. 2005 Oct;129(4):1198-209
– reference: 18297705 - J Med Virol. 2008 Apr;80(4):591-7
– reference: 7875479 - Gastroenterology. 1995 Mar;108(3):768-75
– reference: 18390844 - Carcinogenesis. 2008 Jun;29(6):1192-6
– reference: 2034275 - Nature. 1991 May 23;351(6324):317-20
– reference: 12512035 - Gastroenterology. 2003 Jan;124(1):105-17
– reference: 8521383 - Cancer Res. 1995 Dec 15;55(24):6012-6
– reference: 16250051 - Hepatology. 2005 Nov;42(5):1208-36
– reference: 18223490 - J Clin Gastroenterol. 2008 Mar;42(3):317-22
– reference: 14638411 - Antiviral Res. 2003 Oct;60(2):145-50
– reference: 14699491 - Gastroenterology. 2004 Jan;126(1):91-101
SSID ssj0013058
Score 2.2471852
Snippet Background Prediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We...
Background Prediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We...
Prediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We investigated whether...
SourceID proquest
pubmed
crossref
springer
fao
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 991
SubjectTerms Abdominal Surgery
Antiviral Agents - therapeutic use
Biliary Tract
Carcinoma, Hepatocellular - physiopathology
Carcinoma, Hepatocellular - therapy
Carcinoma, Hepatocellular - virology
Catheter Ablation
Colorectal Surgery
DNA, Viral - blood
Female
Follow-Up Studies
Gastroenterology
Hepatitis B - complications
Hepatitis B virus - genetics
Hepatology
Humans
Liver Neoplasms - physiopathology
Liver Neoplasms - therapy
Liver Neoplasms - virology
Male
Medicine
Medicine & Public Health
Middle Aged
Multivariate Analysis
Neoplasm Recurrence, Local
Original Article—Liver
Pancreas
Retrospective Studies
Risk Factors
Surgical Oncology
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jb9UwELZokRAXVNaGsvjACWSRxFtzqspSVUjtBZ70bpa3QKU2KS-vB_o_-L_MOE6eELSHXBI7Tjxje8Yz_j5C3nDHPVgCNbO1iExEbVkTRMuCbzmsnrFVDvc7Tk7V8UJ8Wcplzs0ZclrlNCemiTr0HvfI39eI6wKrc3Nw-ZMhaRQGVzODxha5i8hlqNR6qTdBhDLRc4IDI1gFlvcU1CwThqjkkqXIAPj07PqvZWmrtf3_LM5_oqVpETraIQ-y9UgPR3E_JHdi94jcO8nx8cfkN0idnk28I7Rv6Y-IKdPrs4F-oJ9OD-k5JglR2wW4kDhiBa8bz2D9on1HV7j9ng4A0sQeDi-DylAGbieIcDpnpsMjmlFZB4rbuWNbPYYCMLeVeqQp6voL-4Qsjj5_-3jMMvEC8-BgrJkVUvgySq9taRsRGyddAMNJczD2vK6Vk0qXKlqr3H5Ar2g_-JJr3wpZBejPp2S767u4S6iVQrSVbZ2LSlQxgLunrK4sDH3dBG0LUk79bnxGJUdyjHMz4yknURkQE17cXBfk7VzlcoTkuK3wLgjT2O8wZZrF1xq1olKISlgVZG-SsMkDdzCzmhXk9fwURhz2ne1ifzUYocAnBTesIPSGEpoLJAgUdUGejZqz-dAG7DfeQOPvJlXaNH7jXzy_9VP3yP0xxoWZby_I9np1FV-CqbR2r9KA-AOgCw9R
  priority: 102
  providerName: ProQuest
Title influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma
URI https://link.springer.com/article/10.1007/s00535-009-0093-z
https://www.ncbi.nlm.nih.gov/pubmed/19554391
https://www.proquest.com/docview/217166009
https://www.proquest.com/docview/46401974
https://www.proquest.com/docview/734050542
Volume 44
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6xrYS4oJZXQ-niAyeQpTwcuznuwi4VqCsErLScLMdxSqWSoM32QH9Iz_wWfhkzzmOFaJE4RJbiV-Lx45uHZwBeJHliEQnE3MTCceGU4VkhSl7YMsHT05UyJ3nH6UKeLMW7Vbrq7nE3vbV7r5L0O_Vw2c27IuFemI9sOL8awW6KrDvZcS3jyVZ1EPqgnMi2CB4h3u5VmTc18cdhNCpNfRPO_EtH6o-e-R7c7zAjm7RE3oc7rnoAd087rfhDuEZas_M-2girS_bVkaH05rz59XPK3iwm7IJsg5ipCnwoXsQa22uvXv1gdcXWJHX39_6YDxqOrWFtLIOvvWdwNhikYxbrnLE2jKS4bWc1aQDIpJVZik5U1d_MI1jOZ59fn_Au3gK3yFdsuBGpsKFLrTKhyYTL8jQvEC-pBDGeVbHMU6lC6YyR-XFBzNBxYcNE2VKkUYED-hh2qrpyB8BMKkQZmTLPnRSRK5DLk0ZFBle8ygplAgj7gde2c0ZOMTEu9OBG2dNKI53oSfRVAC-HKt9bTxz_KnyA1NTmDHdKvfwU07SIJDkjjAI47Emsu_Xa6Ji8BiH2ywJ4PuTiQqOxM5WrLxstJLKiyH0FwG4poRJBcQFFHMCTdupsPzRD2JZk2Pmrfi5tO7_1L57-V-lDuNequsgA7hnsbNaX7ggR0yYfw0it1Bh2J_PpdEHp2y_vZ5hOZ4sPH8d-_fwGdHUTng
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgEXxLNNC9QHuIAs8nDs5oBQoVRb2t0LXWlvwbEdqFSSdrMVav8HP4P_yIzzWCFobz3ksnHsbGY8_sYzng_gZVIkBpFAzHUsHBdOaZ5ZUXJrygRXT1fKgvY7xhM5morPs3S2Ar_7szCUVtnbRG-obW1oj_xtTHVdcHXO3p-ecSKNouBqz6DRasWBu_iJHlvzbn8Xxfsqjvc-HX0c8Y5UgBsEzwuuRSpM6FKjdKgz4bIiLSyCApUgkDEqlkUqVSid1rLYtoT4t60JE2VKkUbW115Ci38b192QfD01U8ugRejpQNFhEjxCpN8HUUNfszRNUu4jEdgHv_xrGbxV6vp_CPef6Kxf9PYewP0OrbKdVr0ewoqrHsGdcRePfwy_UMvYcc9zwuqSfXeUor04btgHtjvZYSeUlMR0ZfEiooo5dtee-bpgdcXmtN3vDxwyz1aOneHD2AZ_9iXJ2ZAJj7dYVwW2YbR93I5VU-iBcmmZIVqkqv6hn8D0RmTyFFarunLrwHQqRBnpsiicFJGz6F5KrSKNpkZlVukAwv6756argk5kHCf5UL_ZiypHMdGV5JcBvB4eOW1LgFzXeB2FmetvaKLz6ZeYtCKSVAUxCmCzl3DeGYomH9Q6gK3hLs5w-na6cvV5kwuJPjC6fQGwK1qoRBAhoYgDWGs1Z_miGeLFJMPB3_SqtBz8yn-xce2rbsHd0dH4MD_cnxxswr02vkZZd89gdTE_d88Rpi2KF35yMPh607PxD3o0SzQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrVRxQbybFqgPcAFZzcOxmwNCLdtVS-mqAlbqLTi2A5VK0u5uhdr_wY_h3zHjPFYI2lsPuWwcO5sZj7_xjOcDeJkUiUEkEHMdC8eFU5pnVpTcmjLB1dOVsqD9jsOx3JuID8fp8RL87s7CUFplZxO9oba1oT3yzZjquuDqnG2WbVbE0XD07uycE4EUBVo7No1GQw7c5U_03mZv94co6ldxPNr98n6PtwQD3CCQnnMtUmFClxqlQ50JlxVpYREgqARBjVGxLFKpQum0lsWWJfS_ZU2YKFOKNLK-DhNa_2VFTtEAlnd2x0efFiGM0JODovskeIS4vwuphr6CaZqk3MclsBd-9deieKfU9f_w7j-xWr8Eju7DvRa7su1G2R7AkqsewsphG51_BL9Q59hJx3rC6pJ9d5SwPT-ZsR02HG-zU0pRYrqyeBFtxRS7a06AXbK6YlPa_PfHD5nnLsfO8GFsgz_7AuWsz4vHW6ytCTtjtJncjFVTIIIya5khkqSq_qEfw-RWpPIEBlVduVVgOhWijHRZFE6KyFl0NqVWkUbDozKrdABh991z09ZEJ2qO07yv5uxFlaOY6EryqwBe94-cNQVBbmq8isLM9Tc02Pnkc0xaEUmqiRgFsN5JOG_NxizvlTyAjf4uznf6drpy9cUsFxI9YnQCA2DXtFCJIHpCEQfwtNGcxYtmiB6TDAd_06nSYvBr_8Xaja-6ASs4E_OP--ODdbjbBNsoBe8ZDObTC_ccMdu8eNHODgZfb3tC_gHUOlDP
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+influence+of+hepatitis+B+DNA+level+and+antiviral+therapy+on+recurrence+after+initial+curative+treatment+in+patients+with+hepatocellular+carcinoma&rft.jtitle=Journal+of+gastroenterology&rft.au=Chuma%2C+Makoto&rft.au=Hige%2C+Shuhei&rft.au=Kamiyama%2C+Toshiya&rft.au=Meguro%2C+Takashi&rft.date=2009-09-01&rft.issn=0944-1174&rft.volume=44&rft.issue=9&rft.spage=991&rft.epage=999&rft_id=info:doi/10.1007%2Fs00535-009-0093-z&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0944-1174&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0944-1174&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0944-1174&client=summon